Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 27 January 2009
Vol. 2, Issue 55, p. ra2
[DOI: 10.1126/scisignal.2000189]


Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis

Caterina Nardella1, Arkaitz Carracedo1*, Andrea Alimonti1*, Robin M. Hobbs1, John G. Clohessy1, Zhenbang Chen1, Ainara Egia1, Alessandro Fornari2,3, Michelangelo Fiorentino2, Massimo Loda2,4, Sara C. Kozma5, George Thomas5, Carlos Cordon-Cardo6, and Pier Paolo Pandolfi1{dagger}

1 Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
3 Department of Biomedical Sciences and Human Oncology, Molinette Hospital, University of Turin, 10126 Turin, Italy.
4 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
5 Department of Genome Science, Genome Research Institute, University of Cincinnati, Cincinnati, OH 45237, USA.
6 Department of Pathology, Columbia University, New York, NY 10032, USA.

* These authors contributed equally to this work.

Abstract: The mammalian target of rapamycin (mTOR) is a crucial effector in a complex signaling network commonly disrupted in cancer. mTOR exerts its multiple functions in the context of two different multiprotein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Loss of the tumor suppressor PTEN (phosphatase and tensin homolog deleted from chromosome 10) can hyperactivate mTOR through AKT and represents one of the most frequent events in human prostate cancer. We show here that conditional inactivation of mTor in the adult mouse prostate is seemingly inconsequential for this postmitotic tissue. Conversely, inactivation of mTor leads to a marked suppression of Pten loss–induced tumor initiation and progression in the prostate. This suppression is more pronounced than that elicited by the sole pharmacological abrogation of mTORC1. Acute inactivation of mTor in vitro also highlights the differential requirement of mTor function in proliferating and transformed cells. Collectively, our data constitute a strong rationale for developing specific mTOR inhibitors targeting both mTORC1 and mTORC2 for the treatment of tumors triggered by PTEN deficiency and aberrant mTOR signaling.

{dagger} To whom correspondence should be addressed. E-mail: ppandolf{at}

Citation: C. Nardella, A. Carracedo, A. Alimonti, R. M. Hobbs, J. G. Clohessy, Z. Chen, A. Egia, A. Fornari, M. Fiorentino, M. Loda, S. C. Kozma, G. Thomas, C. Cordon-Cardo, P. P. Pandolfi, Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis. Sci. Signal. 2, ra2 (2009).

Read the Full Text

Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.
W. Lieberthal and J. S. Levine (2012)
Am J Physiol Renal Physiol 303, F180-F191
   Abstract »    Full Text »    PDF »
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Z. Fang, T. Zhang, N. Dizeyi, S. Chen, H. Wang, K. D. Swanson, C. Cai, S. P. Balk, and X. Yuan (2012)
J. Biol. Chem. 287, 2090-2098
   Abstract »    Full Text »    PDF »
From man to mouse and back again: advances in defining tumor AKTivities in vivo.
D. F. Restuccia and B. A. Hemmings (2010)
Dis. Model. Mech. 3, 705-720
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 21 April 2009.
M. B. Yaffe and A. M. VanHook (2009)
Science Signaling 2, pc8
   Abstract »    Full Text »
The Pharmacology of mTOR Inhibition.
D. A. Guertin and D. M. Sabatini (2009)
Science Signaling 2, pe24
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 03 February 2009.
P. P. Pandolfi and A. M. VanHook (2009)
Science Signaling 2, pc3
   Abstract »    Full Text »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882